Last reviewed · How we verify

Nexavar — Competitive Intelligence Brief

Nexavar (SORAFENIB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinase Inhibitor [EPC]. Area: Oncology.

marketed Kinase Inhibitor [EPC] Vascular endothelial growth factor receptor 2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Nexavar (SORAFENIB) — Bayer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Nexavar TARGET SORAFENIB Bayer marketed Kinase Inhibitor [EPC] Vascular endothelial growth factor receptor 2 2005-01-01
Cyramza RAMUCIRUMAB Eli Lilly marketed Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] Vascular endothelial growth factor receptor 2 2014-01-01
Cometriq CABOZANTINIB Exelixis Inc marketed Kinase Inhibitor Vascular endothelial growth factor receptor 2 2012-01-01
Cometriq Cabometyx Exelixis marketed Kinase Inhibitor Vascular endothelial growth factor receptor 2 2012-01-01
Vermox MEBENDAZOLE marketed Anthelmintic [EPC] Vascular endothelial growth factor receptor 2 1974-01-01
Rivoceranib Apatinib Zhongda Hospital marketed Vascular endothelial growth factor receptor 2
Ramucirumab (IMC-1211B) DP Ramucirumab (IMC-1211B) DP Eli Lilly and Company phase 3 VEGFR2 inhibitor (monoclonal antibody) VEGFR2 (Vascular Endothelial Growth Factor Receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Kinase Inhibitor [EPC] class)

  1. · 12 drugs in this class
  2. Pfizer · 7 drugs in this class
  3. Novartis · 3 drugs in this class
  4. Bayer · 2 drugs in this class
  5. Boehringer Ingelheim · 2 drugs in this class
  6. AstraZeneca · 2 drugs in this class
  7. Beigene Usa Inc · 1 drug in this class
  8. BeiGene · 1 drug in this class
  9. AbbVie · 1 drug in this class
  10. Bristol · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nexavar — Competitive Intelligence Brief. https://druglandscape.com/ci/sorafenib. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: